Small cell carcinoma of the esophagus: A multicentre rare cancer network study

B. Vos, T. Rozema, R. C. Miller, A. Hendlisz, J. L. van Laethem, K. Khanfir, D. C. Weber, I. El Nakadi, P. van Houtte

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Small cell carcinoma of the esophagus (SCCE) is a rare and aggressive malignant tumor with a poor prognosis. The aims of this retrospective study were to analyze the epidemiology, clinical characteristics, and treatment outcomes of these patients. Between 1994 and 2004, 24 patients with SCCE from several centers were reviewed for data on demographics, presenting symptoms, diagnosis, disease stage, type of treatment, and outcome. SCCE occurs in the sixth decade: median age (interquartile range [IQR]): 65 (59-69) years with a male predominance (63%). The most common complaining symptoms were rapidly progressive dysphagia (79%), weight loss (54%), and retrosternal/epigastric pain (46%). The tumor arises primarily in the middle (52%) or in the lower (35%) third of the esophagus. History of tobacco and alcohol exposure was present in 90% and 70% of case, respectively. Extensive disease was present in 13 cases (54%) at initial diagnosis. The overall median survival (IQR) was 11 (8-20) months for all 24 patients, and the 2-year overall survival was 25.1%. Four patients were alive more than 2 years after treatment. Chemotherapy increased the survival compared with symptomatic management in extensive disease (median survival [IQR]: 9.5 [6-14] vs. 6 [4-7] months, P= 0.05). In limited disease, concurrent chemo-radiotherapy was more effective than non-concurrent treatment (median survival [IQR]: 36 [14-93] vs. 11 [9-15] months, P= 0.04). Two patients were treated by surgery and chemoradiation therapy with a survival of 35 and 66 months. Chemotherapy is the cornerstone of treatment of SCCE in all stage. For limited disease SCCE, concurrent chemo-radiotherapy is the primary choice compared with sequential approach. The role of surgery was not assessable in our study.

Original languageEnglish (US)
Pages (from-to)258-264
Number of pages7
JournalDiseases of the Esophagus
Volume24
Issue number4
DOIs
StatePublished - May 2011

Fingerprint

Small Cell Carcinoma
Esophagus
Survival
Neoplasms
Radiotherapy
Drug Therapy
Therapeutics
Deglutition Disorders
Tobacco
Weight Loss
Epidemiology
Retrospective Studies
Alcohols
Demography
Pain

Keywords

  • Chemotherapy
  • Esophagus
  • Radiotherapy
  • Small-cell carcinoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Vos, B., Rozema, T., Miller, R. C., Hendlisz, A., van Laethem, J. L., Khanfir, K., ... van Houtte, P. (2011). Small cell carcinoma of the esophagus: A multicentre rare cancer network study. Diseases of the Esophagus, 24(4), 258-264. https://doi.org/10.1111/j.1442-2050.2010.01133.x

Small cell carcinoma of the esophagus : A multicentre rare cancer network study. / Vos, B.; Rozema, T.; Miller, R. C.; Hendlisz, A.; van Laethem, J. L.; Khanfir, K.; Weber, D. C.; El Nakadi, I.; van Houtte, P.

In: Diseases of the Esophagus, Vol. 24, No. 4, 05.2011, p. 258-264.

Research output: Contribution to journalArticle

Vos, B, Rozema, T, Miller, RC, Hendlisz, A, van Laethem, JL, Khanfir, K, Weber, DC, El Nakadi, I & van Houtte, P 2011, 'Small cell carcinoma of the esophagus: A multicentre rare cancer network study', Diseases of the Esophagus, vol. 24, no. 4, pp. 258-264. https://doi.org/10.1111/j.1442-2050.2010.01133.x
Vos B, Rozema T, Miller RC, Hendlisz A, van Laethem JL, Khanfir K et al. Small cell carcinoma of the esophagus: A multicentre rare cancer network study. Diseases of the Esophagus. 2011 May;24(4):258-264. https://doi.org/10.1111/j.1442-2050.2010.01133.x
Vos, B. ; Rozema, T. ; Miller, R. C. ; Hendlisz, A. ; van Laethem, J. L. ; Khanfir, K. ; Weber, D. C. ; El Nakadi, I. ; van Houtte, P. / Small cell carcinoma of the esophagus : A multicentre rare cancer network study. In: Diseases of the Esophagus. 2011 ; Vol. 24, No. 4. pp. 258-264.
@article{e9153cbb2e7e41d88800b78ee5503c7b,
title = "Small cell carcinoma of the esophagus: A multicentre rare cancer network study",
abstract = "Small cell carcinoma of the esophagus (SCCE) is a rare and aggressive malignant tumor with a poor prognosis. The aims of this retrospective study were to analyze the epidemiology, clinical characteristics, and treatment outcomes of these patients. Between 1994 and 2004, 24 patients with SCCE from several centers were reviewed for data on demographics, presenting symptoms, diagnosis, disease stage, type of treatment, and outcome. SCCE occurs in the sixth decade: median age (interquartile range [IQR]): 65 (59-69) years with a male predominance (63{\%}). The most common complaining symptoms were rapidly progressive dysphagia (79{\%}), weight loss (54{\%}), and retrosternal/epigastric pain (46{\%}). The tumor arises primarily in the middle (52{\%}) or in the lower (35{\%}) third of the esophagus. History of tobacco and alcohol exposure was present in 90{\%} and 70{\%} of case, respectively. Extensive disease was present in 13 cases (54{\%}) at initial diagnosis. The overall median survival (IQR) was 11 (8-20) months for all 24 patients, and the 2-year overall survival was 25.1{\%}. Four patients were alive more than 2 years after treatment. Chemotherapy increased the survival compared with symptomatic management in extensive disease (median survival [IQR]: 9.5 [6-14] vs. 6 [4-7] months, P= 0.05). In limited disease, concurrent chemo-radiotherapy was more effective than non-concurrent treatment (median survival [IQR]: 36 [14-93] vs. 11 [9-15] months, P= 0.04). Two patients were treated by surgery and chemoradiation therapy with a survival of 35 and 66 months. Chemotherapy is the cornerstone of treatment of SCCE in all stage. For limited disease SCCE, concurrent chemo-radiotherapy is the primary choice compared with sequential approach. The role of surgery was not assessable in our study.",
keywords = "Chemotherapy, Esophagus, Radiotherapy, Small-cell carcinoma",
author = "B. Vos and T. Rozema and Miller, {R. C.} and A. Hendlisz and {van Laethem}, {J. L.} and K. Khanfir and Weber, {D. C.} and {El Nakadi}, I. and {van Houtte}, P.",
year = "2011",
month = "5",
doi = "10.1111/j.1442-2050.2010.01133.x",
language = "English (US)",
volume = "24",
pages = "258--264",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Small cell carcinoma of the esophagus

T2 - A multicentre rare cancer network study

AU - Vos, B.

AU - Rozema, T.

AU - Miller, R. C.

AU - Hendlisz, A.

AU - van Laethem, J. L.

AU - Khanfir, K.

AU - Weber, D. C.

AU - El Nakadi, I.

AU - van Houtte, P.

PY - 2011/5

Y1 - 2011/5

N2 - Small cell carcinoma of the esophagus (SCCE) is a rare and aggressive malignant tumor with a poor prognosis. The aims of this retrospective study were to analyze the epidemiology, clinical characteristics, and treatment outcomes of these patients. Between 1994 and 2004, 24 patients with SCCE from several centers were reviewed for data on demographics, presenting symptoms, diagnosis, disease stage, type of treatment, and outcome. SCCE occurs in the sixth decade: median age (interquartile range [IQR]): 65 (59-69) years with a male predominance (63%). The most common complaining symptoms were rapidly progressive dysphagia (79%), weight loss (54%), and retrosternal/epigastric pain (46%). The tumor arises primarily in the middle (52%) or in the lower (35%) third of the esophagus. History of tobacco and alcohol exposure was present in 90% and 70% of case, respectively. Extensive disease was present in 13 cases (54%) at initial diagnosis. The overall median survival (IQR) was 11 (8-20) months for all 24 patients, and the 2-year overall survival was 25.1%. Four patients were alive more than 2 years after treatment. Chemotherapy increased the survival compared with symptomatic management in extensive disease (median survival [IQR]: 9.5 [6-14] vs. 6 [4-7] months, P= 0.05). In limited disease, concurrent chemo-radiotherapy was more effective than non-concurrent treatment (median survival [IQR]: 36 [14-93] vs. 11 [9-15] months, P= 0.04). Two patients were treated by surgery and chemoradiation therapy with a survival of 35 and 66 months. Chemotherapy is the cornerstone of treatment of SCCE in all stage. For limited disease SCCE, concurrent chemo-radiotherapy is the primary choice compared with sequential approach. The role of surgery was not assessable in our study.

AB - Small cell carcinoma of the esophagus (SCCE) is a rare and aggressive malignant tumor with a poor prognosis. The aims of this retrospective study were to analyze the epidemiology, clinical characteristics, and treatment outcomes of these patients. Between 1994 and 2004, 24 patients with SCCE from several centers were reviewed for data on demographics, presenting symptoms, diagnosis, disease stage, type of treatment, and outcome. SCCE occurs in the sixth decade: median age (interquartile range [IQR]): 65 (59-69) years with a male predominance (63%). The most common complaining symptoms were rapidly progressive dysphagia (79%), weight loss (54%), and retrosternal/epigastric pain (46%). The tumor arises primarily in the middle (52%) or in the lower (35%) third of the esophagus. History of tobacco and alcohol exposure was present in 90% and 70% of case, respectively. Extensive disease was present in 13 cases (54%) at initial diagnosis. The overall median survival (IQR) was 11 (8-20) months for all 24 patients, and the 2-year overall survival was 25.1%. Four patients were alive more than 2 years after treatment. Chemotherapy increased the survival compared with symptomatic management in extensive disease (median survival [IQR]: 9.5 [6-14] vs. 6 [4-7] months, P= 0.05). In limited disease, concurrent chemo-radiotherapy was more effective than non-concurrent treatment (median survival [IQR]: 36 [14-93] vs. 11 [9-15] months, P= 0.04). Two patients were treated by surgery and chemoradiation therapy with a survival of 35 and 66 months. Chemotherapy is the cornerstone of treatment of SCCE in all stage. For limited disease SCCE, concurrent chemo-radiotherapy is the primary choice compared with sequential approach. The role of surgery was not assessable in our study.

KW - Chemotherapy

KW - Esophagus

KW - Radiotherapy

KW - Small-cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=79956195078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956195078&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2050.2010.01133.x

DO - 10.1111/j.1442-2050.2010.01133.x

M3 - Article

C2 - 21073624

AN - SCOPUS:79956195078

VL - 24

SP - 258

EP - 264

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 4

ER -